Similarly, the downregulation of FOXO3A likely enhances cancer cell survival and resistance to apoptosis, while the downregulation of cyclin B1 suggests a possible defect in cell cycle regulation, both affecting the prognosis of these patients compared to the patients in the high-muscle/low-adiposity group [40,43]. The gene discussed is FOXO3; the disease is cancer.